Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.

Britain said on July 7 the country would provide genomic sequencing support to Brazil, Ethiopia, Kenya, Nigeria and Pakistan to help identify, assess and track new variants of the novel coronavirus.